New hope for tough bladder cancers: drug targets DNA repair weakness
NCT ID NCT03375307
First seen Sep 30, 2025 · Last updated May 01, 2026 · Updated 35 times
Summary
This study tests a drug called olaparib in people with advanced bladder or urinary tract cancers that have specific DNA repair problems. Olaparib works by blocking a protein that cancer cells need to fix their damaged DNA, which may stop tumor growth. The trial aims to see if the drug can shrink tumors and help people live longer. It is for patients whose cancer has spread and who have certain gene mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
NCI - Center for Cancer Research
Bethesda, Maryland, 20892, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UC San Diego Health System - Encinitas
Encinitas, California, 92024, United States
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
Conditions
Explore the condition pages connected to this study.